Tina Mayer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7218383/publications.pdf

Version: 2024-02-01

10	F 2-7	1040056	839539 1.0
19	537	9	18
papers	citations	h-index	g-index
19	19	19	1050
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glioblastoma Multiforme. Hematology/Oncology Clinics of North America, 2012, 26, 825-853.	2.2	125
2	First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2017, 23, 4163-4169.	7.0	119
3	Plasma Markers for Identifying Patients with Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 2417-2425.	7.0	80
4	Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration., 2019, 7, 136.		48
5	Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clinical Cancer Research, 2018, 24, 306-315.	7.0	38
6	Combination drug regimens for metastatic clear cell renal cell carcinoma. World Journal of Clinical Oncology, 2020, 11, 541-562.	2.3	19
7	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology, 2021, 4, 948-954.	5.4	18
8	Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. Journal of Investigative Medicine, 2010, 58, 566-568.	1.6	17
9	Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International, 2019, 7, 102-107.	2.3	15
10	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers, 2021, 13, 1475.	3.7	10
11	Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 247-257.	1.6	9
12	Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology, 2019, 19, 33.	1.4	8
13	Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 296-296.e9.	1.9	7
14	Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate International, 2022, 10, 75-79.	2.3	7
15	Intra-abdominal seminoma found incidentally during trauma workup in a man with bilateral cryptorchidism. Urology Annals, 2015, 7, 534.	0.6	6
16	Importance of initial aggressive treatment for pineal parenchymal tumor of intermediate differentiation: A case report and review of literature. Practical Radiation Oncology, 2013, 3, e29-e34.	2.1	5
17	Does Certificate of Need Minimize Intensity Modulated Radiation TherapyÂUse in Patients with Low Risk Prostate Cancer?. Urology Practice, 2016, 3, 342-348.	0.5	3
18	Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab. Clinical Genitourinary Cancer, 2017, 15, e165-e167.	1.9	2

#	Article	IF	CITATIONS
19	Dramatic mixed response of lymphangitic pulmonary metastases in newly diagnosed prostate cancer. Urology Annals, 2017, 9, 278.	0.6	1